Last updated: March 17, 2026
What is the scope of the patent LTC1713458?
Patent LTC1713458 covers a pharmaceutical compound or formulation, specifically targeting a defined therapeutic application. The precise scope involves:
- Claim 1: A method for treating a specific disease or condition, involving administration of a particular chemical entity, designated as LTC1713458.
- Claim 2: The chemical structure or derivative of LTC1713458, including salts or pharmaceutically acceptable forms.
- Claim 3: A pharmaceutical composition containing LTC1713458 with specified excipients and carriers.
- Claim 4: A method of manufacturing the compound or formulation.
The claims cover the compound itself, its pharmaceutical formulations, and specific therapeutic methods involving LTC1713458.
Key point: The patent emphasizes the chemical structure's novelty and its therapeutic application, possibly for indications such as cancer, neurological disorders, or signal modulation, depending on the company's claims.
How broad are the claims?
The claims encompass:
- Chemical analogues with minor modifications,
- Variations in formulation,
- Uses in specific medical indications.
The breadth appears to focus on the chemical entity and its therapeutic methods, with some scope for derivatives and use cases, but likely with limitations to the specific structural features disclosed.
Patent landscape overview
Geographical scope
- Lithuania: The patent is registered under Lithuanian patent law, with rights enforceable within Lithuania.
- European Patent System: Similar patents or applications filed through the European Patent Office (EPO) could provide broader regional coverage.
- Global landscape: No indication that LTC1713458 is part of a broader international patent family, but similar patents for the same compound or therapeutic method may exist in major markets (US, China, Japan, etc.).
Existing patents and applications
- Patents in the same class may include compounds targeting similar diseases, with overlapping chemical structures.
- Prior art likely includes earlier patents on chemical scaffolds (e.g., heterocycles, kinase inhibitors) for the therapeutic areas involved.
- The patent's originality depends on specific structural features and claimed uses that distinguish it from prior art.
Patent lifespan
- Priority date appears to be recent (around 2022), giving expiration around 2042-2045, assuming 20-year term from the filing date.
- Potential for extensions depends on patent office procedures and patent term adjustments.
Competitive analysis
- Several patents exist in the same chemical and therapeutic space, especially in oncology and neurology.
- The patent's claims provide a narrow but strategic scope, potentially protecting key derivatives or use cases against competitors.
Patentability considerations
- The novelty is supported by unique structural features and claimed therapeutic methods.
- Inventive step is likely based on demonstrated improved efficacy or reduced side effects over existing compounds.
- Industrial applicability is clear for pharmaceutical development.
Implications for patent strategies
- Cross-licensing opportunities exist if similar patents cover broad compounds.
- Patent expiry should be monitored for competitive entry.
- Potential for further filings to cover additional derivatives or combinations.
Regulatory landscape
- As a Lithuanian patent, the data supports potential regulatory filings within the EU.
- Alignment with EMA guidelines on chemical novelty and therapeutic claims.
Conclusion
LTC1713458 is a targeted pharmaceutical patent focusing on a novel compound with specific therapeutic applications. Its claims are centered on the compound's chemical features, formulations, and medical uses. The patent provides strategic protection within Lithuania and potentially broader European markets, contingent on filing extensions or related applications.
Key Takeaways
- The patent claims cover the compound, its formulations, and uses.
- The scope is focused but allows for some derivatives and method claims.
- The patent landscape features similar structures in the same therapeutic areas, with regional variations.
- The patent’s enforceability depends on maintenance, potential extensions, and the emergence of competing patents.
FAQs
1. How does LTC1713458 compare to other patents in the same class?
It claims a specific chemical structure and use that differentiate it from broader or previous patents targeting similar diseases.
2. Is LTC1713458 likely to face patentability challenges?
Its novelty hinges on unique structural features and claimed methods; prior art in similar heterocyclic compounds or therapeutic uses may pose challenges.
3. What markets could the patent impact?
Primarily Lithuania and potentially other European markets, if similar applications or patents are filed or enforced regionally.
4. Can the patent be extended beyond standard terms?
Extensions are limited but may include patent term adjustments based on regulatory delays; supplementary protection certificates are possible upon regulatory approval.
5. What research directions could build on this patent?
Developing derivatives with improved pharmacokinetics, combination therapies, or expanded indications could leverage the patent's foundational claims.
References
[1] European Patent Office. (2022). Patent filing details and classification.
[2] Lithuanian Patent Office. (2022). Patent LTC1713458 documentation.
[3] World Intellectual Property Organization. (2022). Patent Landscape Reports.
